Frey-Met G2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, designed to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, works by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The sustained-release (SR) formulation ensures a gradual release of the active ingredients, providing prolonged therapeutic effects and minimizing gastrointestinal side effects commonly associated with metformin. Frey-Met G2 is typically prescribed when diet, exercise, and monotherapy with either agent fail to achieve adequate glycemic control. It helps reduce fasting and postprandial blood glucose levels, thereby lowering the risk of diabetes-related complications such as neuropathy, nephropathy, and retinopathy. Patients should take this medication as directed by their healthcare provider, usually once daily with meals to enhance absorption and reduce gastrointestinal discomfort. Regular monitoring of blood glucose and renal function is recommended during therapy. Frey-Met G2 is contraindicated in patients with severe renal impairment, diabetic ketoacidosis, or hypersensitivity to its components. Proper adherence to therapy, combined with lifestyle modifications, can significantly improve diabetes management and patient outcomes.